Together with our academic collaborators at the Leiden University Medical Center (LUMC), Hybridize Pharma is fully committed to aid in the development of RNA-based therapeutic options that could serve as a First Line of Defence against Covid-19, and potential future coronavirus-related outbreaks.
Naturally, the focus of medical attention for Covid-19 has been the alleviation of respiratory distress or disease. However, accumulating clinical evidence suggests that extrapulmonary sites of infection are contributing factors to the observed high morbidity and mortality rates. Moreover, the long-term consequences of infection on human health are unclear.
The ongoing Covid-19 pandemic has made it painfully clear that in spite of compliance with social distancing efforts (to ‘flatten the curve’) and top-tier medical care (hospitalization in intensive care unit and oxygen support), the number of infected individuals continues to rise. Worldwide this has led to an alarmingly high healthcare burden. While the global population anxiously awaits the successful development of a SARS-CoV-2 vaccine, the dire need for a ‘First Line of Defence’ against the virus have arisen, as at present, suitable therapeutic options are non-existent.